Der Nervenarzt

, Volume 82, Issue 6, pp 768–777 | Cite as

Diagnostik und Therapie der Neuromyelitis optica

Konsensusempfehlungen der Neuromyelitis optica Studiengruppe
  • C. Trebst
  • A. Berthele
  • S. Jarius
  • T. Kümpfel
  • S. Schippling
  • B. Wildemann
  • C. Wilke
  • Neuromyelitis optica Studiengruppe (NEMOS)
Aktuelles aus Diagnostik und Therapie

Diagnosis and treatment of neuromyelitis optica

Consensus recommendations of the Neuromyelitis Optica Study Group

Literatur

  1. 1.
    Aktas O, Hartung HP (2009) Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. J Neurol 256:1906–1908PubMedCrossRefGoogle Scholar
  2. 2.
    Bakker J, Metz L (2004) Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31:265–267PubMedGoogle Scholar
  3. 3.
    Balcer LJ (2006) Clinical practice. Optic neuritis. N Engl J Med 354:1273–1280PubMedCrossRefGoogle Scholar
  4. 4.
    Barbieri F, Buscaino GA (1989) Neuromyelitis optica in the elderly. Acta Neurol 11:247–251Google Scholar
  5. 5.
    Barkhof F, Filippi M, Miller DH et al (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069PubMedCrossRefGoogle Scholar
  6. 6.
    Bergamaschi R (2003) Glatiramer acetate treatment in Devic’s neuromyelitis optica. Brain 126:1E-aPubMedCrossRefGoogle Scholar
  7. 7.
    Bergamaschi R, Jarius S, Robotti M et al (2009) Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol 256:2097–2099PubMedCrossRefGoogle Scholar
  8. 8.
    Bergamaschi R, Tonietti S, Franciotta D et al (2004) Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 10:2–4PubMedCrossRefGoogle Scholar
  9. 9.
    Bergamaschi R, Uggetti C, Tonietti S et al (2003) A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 250:359–361PubMedCrossRefGoogle Scholar
  10. 10.
    Bizzoco E, Lolli F, Repice AM et al (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256:1891–1898PubMedCrossRefGoogle Scholar
  11. 11.
    Bonnet F, Mercie P, Morlat P et al (1999) Devic’s neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus 8:244–247PubMedCrossRefGoogle Scholar
  12. 12.
    Cree BA, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272PubMedGoogle Scholar
  13. 13.
    Davis R, Thiele E, Barnes P, Riviello JJ Jr (1996) Neuromyelitis optica in childhood: case report with sequential MRI findings. J Child Neurol 11:164–167PubMedCrossRefGoogle Scholar
  14. 14.
    Seze J de, Stojkovic T, Ferriby D et al (2002) Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 197:57–61PubMedCrossRefGoogle Scholar
  15. 15.
    Filippi M, Rocca MA (2004) MR imaging of Devic’s neuromyelitis optica. Neurol Sci 25(Suppl 4):371–373CrossRefGoogle Scholar
  16. 16.
    Gartzen K, Limmroth V, Putzki N (2007) Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol 14:12–13CrossRefGoogle Scholar
  17. 17.
    Ghezzi A, Bergamaschi R, Martinelli V et al (2004) Clinical characteristics, course and prognosis of relapsing Devic’s neuromyelitis optica. J Neurol 251:47–52PubMedCrossRefGoogle Scholar
  18. 18.
    Gold R, Hartung HP, Hohlfeld R et al (2009) Therapie der Multiplen Sklerose mit monoklonalen Antikörpern. Ergebnisse und Empfehlungen einer Arbeitstagung des Ärztlichen Beirats der Deutschen Multiple Sklerose Gesellschaft. Akt Neurol 36:334–344CrossRefGoogle Scholar
  19. 19.
    Hayakawa S, Mori M, Okuta A et al (2008) Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 196:181–187PubMedCrossRefGoogle Scholar
  20. 20.
    Herrmann W, Obeid R (2008) Ursachen und frühzeitige Diagnostik von Vitamin-B12-Mangel. Dtsch Arztebl 105:680–685Google Scholar
  21. 21.
    Jacob A, Matiello M, Weinshenker BG et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66:1128–1133PubMedCrossRefGoogle Scholar
  22. 22.
    Jacob A, Weinshenker BG (2008) An approach to the diagnosis of acute transverse myelitis. Semin Neurol 28:105–120PubMedCrossRefGoogle Scholar
  23. 23.
    Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443–1448PubMedCrossRefGoogle Scholar
  24. 24.
    Jarius S, Aboul-Enein F, Waters P et al (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131:3072–3080PubMedCrossRefGoogle Scholar
  25. 25.
    Jarius S, Franciotta D, Bergamaschi R et al (2008) Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 79:1134–1136PubMedCrossRefGoogle Scholar
  26. 26.
    Jarius S, Franciotta D, Bergamaschi R et al (2010) Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 48:659–663PubMedCrossRefGoogle Scholar
  27. 27.
    Jarius S, Franciotta D, Bergamaschi R et al (2007) NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68:1076–1077PubMedCrossRefGoogle Scholar
  28. 28.
    Jarius S, Franciotta D, Paul F et al (2010) Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 7:52PubMedCrossRefGoogle Scholar
  29. 29.
    Jarius S, Frederikson J, Waters P et al (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298:158–162PubMedCrossRefGoogle Scholar
  30. 30.
    Jarius S, Jacob S, Waters P et al (2008) Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. J Neurol Neurosurg Psychiatry 79:1084PubMedCrossRefGoogle Scholar
  31. 31.
    Jarius S, Paul F, Franciotta D et al (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4:202–214PubMedGoogle Scholar
  32. 32.
    Jarius S, Probst C, Borowski K et al (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52–56PubMedCrossRefGoogle Scholar
  33. 33.
    Jarius S, Wildemann B (2007) Neuromyelitis optica. Nervenarzt 78:1365–1377PubMedCrossRefGoogle Scholar
  34. 34.
    Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383–392PubMedCrossRefGoogle Scholar
  35. 35.
    Kalluri SR, Illes Z, Srivastava R et al (2010) Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 67:1201–1208PubMedCrossRefGoogle Scholar
  36. 36.
    Kay CS, Scola RH, Lorenzoni PJ et al (2008) NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci 275:148–150PubMedCrossRefGoogle Scholar
  37. 37.
    Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126:276–284PubMedCrossRefGoogle Scholar
  38. 38.
    Kim W, Min SP, Sang HL et al (2010) Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 16:1229–1236PubMedCrossRefGoogle Scholar
  39. 39.
    Klawiter EC, Alvarez E III, Xu J et al (2009) NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 72:1101–1103PubMedCrossRefGoogle Scholar
  40. 40.
    Krampla W, Aboul-Enein F, Jecel J et al (2009) Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 19:2535–2543PubMedCrossRefGoogle Scholar
  41. 41.
    Lee DH, Metz I, Berthele A et al (2010) Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol Appl Neurobiol (Epub ahead of print)Google Scholar
  42. 42.
    Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477PubMedCrossRefGoogle Scholar
  43. 43.
    Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112PubMedCrossRefGoogle Scholar
  44. 44.
    Lim BC, Hwang H, Kim KJ et al (2010) Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. Mult Scler (Epub ahead of print)Google Scholar
  45. 45.
    Llufriu S, Castillo J, Blanco Y et al (2009) Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 73:949–953PubMedCrossRefGoogle Scholar
  46. 46.
    Lotze TE, Northrop JL, Hutton GJ et al (2008) Spectrum of pediatric neuromyelitis optica. Pediatrics 122:1039–1047CrossRefGoogle Scholar
  47. 47.
    Lucchinetti CF, Mandler RN, McGavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461PubMedCrossRefGoogle Scholar
  48. 48.
    Mader S, Lutterotti A, Di Pauli F et al (2010) Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 5:e10455PubMedCrossRefGoogle Scholar
  49. 49.
    Mandler RN, Ahmed W, Dencoff JE (1998) Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219–1220PubMedGoogle Scholar
  50. 50.
    Mandler RN, Davis LE, Jeffery DR, Kornfeld M (1993) Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 34:162–168PubMedCrossRefGoogle Scholar
  51. 51.
    Matiello M, Lennon VA, Jacob A et al (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70:2197–2200PubMedCrossRefGoogle Scholar
  52. 52.
    McKeon A, Lennon VA, Jacob A et al (2009) Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 39:87–90PubMedCrossRefGoogle Scholar
  53. 53.
    Minagar A, Sheremara W (2000) Treatment of Devic’s disease with methotrexate and prednisone. Int J MS Care 2:39–43Google Scholar
  54. 54.
    Miyamoto K, Kusunoki S (2009) Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13:505–508PubMedCrossRefGoogle Scholar
  55. 55.
    Mok CC, To CH, Mak A, Poon WL (2008) Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 35:172–174PubMedGoogle Scholar
  56. 56.
    Nakamura M, Misu T, Fujihara K et al (2009) Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 15:695–700PubMedCrossRefGoogle Scholar
  57. 57.
    O’Riordan JI, Gallagher HL, Thompson AJ et al (1996) Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 60:382–387CrossRefGoogle Scholar
  58. 58.
    Okada K, Tsuji S, Tanaka K (2007) Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 46:1671–1672PubMedCrossRefGoogle Scholar
  59. 59.
    Papeix C, Vidal JS, Seze J de et al (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13:256–259PubMedCrossRefGoogle Scholar
  60. 60.
    Paty DW, Oger JJ, Kastrukoff LF et al (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180–185PubMedGoogle Scholar
  61. 61.
    Paul F, Jarius S, Aktas O et al (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4:e133PubMedCrossRefGoogle Scholar
  62. 62.
    Paul F, Jarius S, Glumm R et al (2008) Recent findings in pathogenesis, diagnostics and therapy of neuromyelitis optica. Dtsch Med Wochenschr 133:1125–1129PubMedCrossRefGoogle Scholar
  63. 63.
    Petzold A, Pittock S, Lennon V et al (2010) Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 81:109–111PubMedCrossRefGoogle Scholar
  64. 64.
    Pittock SJ, Lennon VA (2008) Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 65:629–632PubMedCrossRefGoogle Scholar
  65. 65.
    Pittock SJ, Lennon VA, Seze J de et al (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65:78–83PubMedCrossRefGoogle Scholar
  66. 66.
    Pittock SJ, Lennon VA, Krecke K et al (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63:390–396PubMedCrossRefGoogle Scholar
  67. 67.
    Pittock SJ, Weinshenker BG, Lucchinetti CF et al (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63:964–968PubMedCrossRefGoogle Scholar
  68. 68.
    Riphagen J, Modderman P, Verrips A (2010) Hiccups, nausea, and vomiting: water channels under attack! Lancet 375:954PubMedCrossRefGoogle Scholar
  69. 69.
    Sellner J, Boggild M, Clanet M et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17:1019–1032PubMedCrossRefGoogle Scholar
  70. 70.
    Shibasaki H, McDonald WI, Kuroiwa Y (1981) Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci 49:253–271PubMedCrossRefGoogle Scholar
  71. 71.
    Shimizu J, Hatanaka Y, Hasegawa M et al (2010) IFN(beta)-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75:1423–1427PubMedCrossRefGoogle Scholar
  72. 72.
    Shimizu Y, Yokoyama K, Misu T et al (2008) Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 255:305–307PubMedCrossRefGoogle Scholar
  73. 73.
    Takahashi T, Fujihara K, Nakashima I et al (2006) Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 210:307–313PubMedCrossRefGoogle Scholar
  74. 74.
    Takahashi T, Miyazawa I, Misu T et al (2008) Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 79:1075–1078PubMedCrossRefGoogle Scholar
  75. 75.
    Tanaka M, Tanaka K, Komori M (2009) Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 62:167–170PubMedCrossRefGoogle Scholar
  76. 76.
    Wandinger KP, Stangel M, Witte T et al (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric SLE and primary Sjögren’s syndrome. Arthritis Rheum 62:1198–1200PubMedCrossRefGoogle Scholar
  77. 77.
    Watanabe S, Misu T, Miyazawa I et al (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13:968–974PubMedCrossRefGoogle Scholar
  78. 78.
    Watanabe S, Nakashima I, Misu T et al (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13:128–132PubMedCrossRefGoogle Scholar
  79. 79.
    Waters P, Jarius S, Littleton E et al (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65:913–919PubMedCrossRefGoogle Scholar
  80. 80.
    Weinshenker BG, O’Brien PC, Petterson TM et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886PubMedCrossRefGoogle Scholar
  81. 81.
    Weinshenker BG, Wingerchuk DM, Vukusic S et al (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566–569PubMedCrossRefGoogle Scholar
  82. 82.
    Weinstock-Guttman B, Ramanathan M, Lincoff N et al (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63:957–963PubMedCrossRefGoogle Scholar
  83. 83.
    Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114PubMedGoogle Scholar
  84. 84.
    Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815PubMedCrossRefGoogle Scholar
  85. 85.
    Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489PubMedCrossRefGoogle Scholar
  86. 86.
    Wingerchuk DM, Weinshenker BG (2008) Neuromyelitis optica. Curr Treat Options Neurol 10:55–66PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • C. Trebst
    • 1
  • A. Berthele
    • 2
  • S. Jarius
    • 3
  • T. Kümpfel
    • 4
  • S. Schippling
    • 5
  • B. Wildemann
    • 3
  • C. Wilke
    • 6
  • Neuromyelitis optica Studiengruppe (NEMOS)
  1. 1.Neurologische KlinikMedizinische Hochschule HannoverHannoverDeutschland
  2. 2.Technische Universität MünchenMünchenDeutschland
  3. 3.Universitätsklinikum HeidelbergHeidelbergDeutschland
  4. 4.Ludwig-Maximilians-UniversitätMünchenDeutschland
  5. 5.Universitätsklinikum Hamburg EppendorfHamburgDeutschland
  6. 6.HELIOS Vorgtland-KlinikumPlauenDeutschland

Personalised recommendations